CPSE:ALK B

Stock Analysis Report

Executive Summary

ALK-Abelló A/S, a pharmaceutical company, develops and markets products and services for allergy and allergic asthma in Europe, North America, and internationally.

Snowflake

Fundamentals

Reasonable growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has ALK-Abelló's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

2.1%

CPSE:ALK B

1.1%

DK Pharmaceuticals

1.6%

DK Market


1 Year Return

20.4%

CPSE:ALK B

8.3%

DK Pharmaceuticals

6.8%

DK Market

ALK B outperformed the Pharmaceuticals industry which returned 7% over the past year.

ALK B outperformed the Market in Denmark which returned 5.7% over the past year.


Share holder returns

ALK BIndustryMarket
7 Day2.1%1.1%1.6%
30 Day-4.4%0.3%0.7%
90 Day-15.7%0.9%0.4%
1 Year20.4%20.4%14.3%8.3%10.1%6.8%
3 Year43.5%42.8%22.9%9.2%31.3%20.4%
5 Year95.1%91.8%25.2%4.6%63.3%39.4%

Price Volatility Vs. Market

How volatile is ALK-Abelló's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ALK-Abelló undervalued based on future cash flows and its price relative to the stock market?

4.63x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

ALK-Abelló's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

ALK-Abelló's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

ALK-Abelló is loss making, we can't compare its value to the Europe Pharmaceuticals industry average.

ALK-Abelló is loss making, we can't compare the value of its earnings to the Denmark market.


Price Based on Expected Growth

Unable to calculate PEG ratio for ALK-Abelló, we can't assess if its growth is good value.


Price Based on Value of Assets

ALK-Abelló is overvalued based on assets compared to the Europe Pharmaceuticals industry average.


Next Steps

Future Growth

How is ALK-Abelló expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

66.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

ALK-Abelló's revenue is expected to grow by 10.1% yearly, however this is not considered high growth (20% yearly).

ALK-Abelló's earnings are expected to grow significantly at over 20% yearly.

ALK-Abelló's revenue growth is expected to exceed the Denmark market average.

ALK-Abelló's earnings growth is expected to exceed the Denmark market average.

ALK-Abelló's earnings growth is expected to exceed the low risk savings rate of 0.2%.


Earnings per Share Growth Estimates


Future Return on Equity

ALK-Abelló is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has ALK-Abelló performed over the past 5 years?

-49.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

ALK-Abelló does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare ALK-Abelló's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare ALK-Abelló's 1-year growth to the Europe Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if ALK-Abelló has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if ALK-Abelló has efficiently used its assets last year compared to the Europe Pharmaceuticals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if ALK-Abelló improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is ALK-Abelló's financial position?


Financial Position Analysis

ALK-Abelló is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

ALK-Abelló's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

ALK-Abelló's level of debt (23.1%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has increased over the past 5 years (14.2% vs 23.1% today).

Operating cash flow is negative therefore debt is not well covered.

Unable to confirm if the interest payments on ALK-Abelló's debt are well covered by earnings due to lack of past financial data.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 2.8x debt.


Next Steps

Dividend

What is ALK-Abelló's current dividend yield, its reliability and sustainability?

0.18%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Unable to evaluate ALK-Abelló's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate ALK-Abelló's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as ALK-Abelló has not reported any payouts.

Unable to verify if ALK-Abelló's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as ALK-Abelló has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of ALK-Abelló's dividends in 3 years as they are not expected to pay a notable one for Denmark.


Next Steps

Management

What is the CEO of ALK-Abelló's salary, the management and board of directors tenure and is there insider trading?

2.5yrs

Average management tenure


CEO

Carsten Hellmann (55yo)

3.3yrs

Tenure

0

Mr. Carsten Hellmann has been the Chief Executive Officer and President at ALK-Abelló A/S since May 17, 2016. Mr. Hellmann serves as the Chief Executive Officer at Merial Inc., Merial New Zealand Limited a ...


Management Age and Tenure

2.5yrs

Average Tenure

50yo

Average Age

The tenure for the ALK-Abelló management team is about average.


Board Age and Tenure

4.7yrs

Average Tenure

58yo

Average Age

The tenure for the ALK-Abelló board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Carsten Hellmann (55yo)

    President

    • Tenure: 3.3yrs
  • Hendrik Nolte

    Senior Vice President of Research & Development - North America and International Markets

    • Tenure: 2.5yrs
  • Henrik Jacobi (54yo)

    Executive VP of Research & Development and Member of Board of Management

    • Tenure: 0yrs
  • Per Plotnikof

    Vice President of Corporate Communications

    • Tenure: 0yrs
  • Søren Jelert (47yo)

    Group CFO

    • Tenure: 1.8yrs
  • Katja Thalund (50yo)

    Senior CMC Project Manager & Director

    • Tenure: 8.7yrs
    • Compensation: ø275.00k
  • Søren Niegel (48yo)

    Executive VP of Commercial Operations & Member of Management Board

    • Tenure: 7.3yrs
  • Miles Guralnick

    President of ALK Abelló Source Materials Inc

    • Tenure: 0yrs
  • Christian Houghton

    Head of Product Supply

    • Tenure: 0.7yrs

Board Members

  • Steen Risgaard (68yo)

    Chairman of the Board

    • Tenure: 7.7yrs
    • Compensation: ø1.08m
  • Lene Skole-Sørensen (60yo)

    Vice Chairman of the Board

    • Tenure: 4.5yrs
    • Compensation: ø650.00k
  • Lars Holmqvist (60yo)

    Director

    • Tenure: 4.5yrs
    • Compensation: ø375.00k
  • Jakob Riis (53yo)

    Director

    • Tenure: 6.5yrs
    • Compensation: ø425.00k
  • Jacob Kastrup (58yo)

    Employee-elected Director

    • Tenure: 8.7yrs
    • Compensation: ø275.00k
  • Katja Thalund (50yo)

    Senior CMC Project Manager & Director

    • Tenure: 8.7yrs
    • Compensation: ø275.00k
  • Vincent Warnery (51yo)

    Independent Director

    • Tenure: 0.5yrs
  • Andreas Holst (66yo)

    Employee-elected Director

    • Tenure: 4.7yrs
    • Compensation: ø275.00k
  • Gonzalo De Miquel (52yo)

    Independent Director

    • Tenure: 1.5yrs
    • Compensation: ø525.00k

Company Information

ALK-Abelló A/S's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ALK-Abelló A/S
  • Ticker: ALK B
  • Exchange: CPSE
  • Founded: 1923
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ø14.676b
  • Shares outstanding: 10.89m
  • Website: https://www.alk.net

Number of Employees


Location

  • ALK-Abelló A/S
  • Bøge Allé 6-8
  • Hørsholm
  • Capital Region of Denmark
  • 2970
  • Denmark

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALK BCPSE (OMX Nordic Exchange Copenhagen)YesB Ordinary SharesDKDKKDec 2005
0OIRLSE (London Stock Exchange)YesB Ordinary SharesGBDKKDec 2005
4AJDB (Deutsche Boerse AG)YesB Ordinary SharesDEEURDec 2005
AKBL.FOTCPK (Pink Sheets LLC)YesB Ordinary SharesUSUSDDec 2005
ALKBCBATS-CHIXE (BATS 'Chi-X Europe')YesB Ordinary SharesGBDKKDec 2005
AKAB.YOTCPK (Pink Sheets LLC)SPONSORED ADRUSUSDSep 2013

Biography

ALK-Abelló A/S, a pharmaceutical company, develops and markets products and services for allergy and allergic asthma in Europe, North America, and internationally. The company offers allergy immunotherapy  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/17 20:59
End of Day Share Price2019/09/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.